KLOTEN, Switzerland, May 3, 2006 (PRIMEZONE) -- Nobel Biocare Holding AG's (Other OTC:NBCHF) Annual General Meeting in Zurich, Switzerland, today endorsed all proposals put forward by the Board of Directors.
The Annual General Meeting approved a dividend of CHF 3.50 gross per bearer share of CHF 2.00 nom. on the share capital entitled to dividends = total CHF 91 139 164.
The dividend will be paid on 8 May, 2006, which is also the ex-dividend day.
The Annual General Meeting also approved the conversion of CHF 600,000,000 of general reserves into the free reserves. As announced on 7 April 2006, this conversion was a prerequisite for the implementation of a new share buy-back program of the Group and the funding of the program with the purchase of shares on a second trading line on virt-x which will open 8 May 2006,
The following Board members were re-elected: Antoine Firmenich, Robert Lilja, Jane Royston, Rolf Soiron and Ernst Zaengerle. Michel Orsinger left after two years on the Nobel Biocare Board.
Stig Eriksson and Domenico Scala were elected as new board members. According to the by-laws, all Board members have been elected for a one-year term.
At the first board meeting following the Annual General Meeting, Rolf Soiron has been re-elected as Chairman of the Board.
KPMG Fides Peat, Zurich, has been re-elected for a one-year term of office as auditor and group auditor.
The interim report for the first quarter 2006 was published today, 3 May 2006.
The interim report for the first six months will be published on 10 August 2006 and the interim report for the first nine months will be published on 19 October 2006.
Disclaimer:
This release may contain forward-looking statements including, but not limited to, projections of future performance of materials and products, financial conditions, results of operations and cash flows, containing risks and uncertainties. These statements are subject to change based on unknown risks and other factors that could cause the actual results or performance to differ materially from the statements made herein.
Nobel Biocare is a medical devices group and the world leader in innovative esthetic dental solutions with its brands Branemark System(r), NobelSpeedy(tm), NobelReplace(tm), NobelPerfect(r), NobelDirect(r), Replace(r) Select, NobelGuide(tm) (dental implants) and Procera(r) (individualized dental prosthetics). Nobel Biocare is a one-stop shop for restorative esthetic dentistry based on science, offering a wide range of innovative Crown and Bridge and Implant products, as well as training and education and clinically documented treatment concepts.
Nobel Biocare has some 1,800 employees and recorded revenue of EUR 485 million in 2005. The company is domiciled in Zurich, Switzerland with headquarters in Zurich and in Gothenburg, Sweden. Production takes place at four production sites located in Sweden and the USA. Nobel Biocare has direct sales organizations in 33 countries. The shares of the parent company Nobel Biocare Holding AG are listed on the SWX Swiss Exchange and on the Stockholm Stock Exchange, Sweden.